Aethlon Medical Achieves Milestone in Oncology Trials
Aethlon Medical, Inc. (Nasdaq: AEMD), a frontrunner in medical therapeutics, is thrilled to announce a significant milestone in its ongoing efforts to treat cancer. The company has successfully enrolled its first patient in a groundbreaking clinical trial examining the efficacy of the Hemopurifier® device in treating solid tumors. This trial, focused on patients who are not responding to anti-PD-1 antibody therapies, signals a hopeful direction in cancer treatment.
Trial Overview and Objectives
This clinical trial is a safety, feasibility, and dose-finding study designed to test the Hemopurifier® in patients suffering from solid tumors. These patients often continue to experience stable or progressive disease despite receiving treatments like Keytruda® (pembrolizumab) or Opdivo® (nivolumab). This innovative study, designated AEMD-2022-06, aims to determine the overall effectiveness of the Hemopurifier in improving treatment responses.
Inclusion of First Patient
The first patient was enrolled by Professor Michael Brown and his team at the Cancer Clinical Trials Unit located at the Royal Adelaide Hospital. Complete eligibility screening was achieved on November 8, 2024, and the patient has entered a two-month run-in period during which they receive standard anti-PD-1 therapy.
Focus on Extracellular Vesicles
During this two-month phase, vital measurements will be taken concerning Extracellular vesicles (EVs) and anti-tumor T cell activity. Should imaging studies reveal no significant tumor improvement, the patient will receive treatment with the Hemopurifier, enabling researchers to closely monitor EV concentrations and T cell activity afterward.
Significance of the Hemopurifier®
The Hemopurifier is a a unique immunotherapeutic device specifically designed to capture and remove harmful EVs from the bloodstream, potentially offering a new level of efficacy for patients undergoing anti-PD-1 therapies. Currently, approximately 30% of patients responding to treatments like pembrolizumab or nivolumab experience any long-term clinical benefit, highlighting the urgent need for alternate solutions. By intercepting these EVs, the Hemopurifier may enhance treatment response rates dramatically, paving the way for better overall patient outcomes.
Clinical Trial Design and Expectations
This clinical trial involves approximately nine to 18 patients who will be monitored for adverse side effects and significant changes in lab results throughout the study. Following the initial run-in period, non-responding patients may qualify to enter the Hemopurifier treatment phase, which includes a structured sequence of therapies aimed at gauging EV concentration decreases and subsequent immune responses.
Study Impact and Future Research
Aethlon Medical anticipates that data from this study could inform future research and regulatory processes, including the design of a comprehensive efficacy and safety trial for potential market approval. Success in this area could lead to a paradigm shift in cancer therapeutics.
About Aethlon Medical and Its Innovations
Aethlon Medical is steadfastly focused on developing advanced therapeutic solutions, notably the Hemopurifier. This FDA-designated Breakthrough Device has demonstrated remarkable potential not only in removing viruses from bloodstream but also in eliminating harmful exosomes that promote cancer progression. These applications hold promises for innovative treatments for cancer and severe viral infections.
Frequently Asked Questions
What is the Hemopurifier?
The Hemopurifier is an immunotherapeutic device designed by Aethlon Medical to remove harmful extracellular vesicles from the bloodstream, with the goal of enhancing the efficacy of cancer therapies.
When did the trial begin?
The trial involving the Hemopurifier's application for patients not responding to anti-PD-1 therapy started upon the enrollment of the first patient, recently completed all initial screening phases.
What is the purpose of this clinical trial?
This trial aims to assess the safety and effectiveness of the Hemopurifier in patients with solid tumors who are not achieving favorable responses from existing anti-PD-1 therapies.
How many patients are expected to be involved?
The clinical trial is designed to include between nine to 18 patients, allowing researchers to monitor treatment effects and safety comprehensively.
How might this research impact future cancer treatments?
If successful, this research has the potential to revolutionize cancer treatment approaches by improving response rates among patients who traditionally do not benefit from existing therapies.
